Risk factors for end-stage renal disease in patients with trauma and stage 3 acute kidney injury

Kyunghak Choi, MDa, Min Soo Kim, MDb, Min Ae Keum, MDa, Seongho Choi, MDa, Kyu-Hyouck Kyoung, MD, PhDa, Jihoon T. Kim, MD, PhDa, Sungjeep Kim, MD, PhDa, Minsu Noh, MDa,∗

Abstract
Research on long-term renal outcomes in patients with acute kidney injury (AKI) and trauma, especially those with traumatic brain injury (TBI), has been limited.

In this study, we enrolled patients with stage 3 AKI as per the Kidney Disease Improving Global Outcomes guidelines, who initiated renal replacement therapy (RRT). These patients were divided into 2 groups depending on the presence of TBI. Comparing the baseline characteristics and management strategies of each group, we analyzed whether TBI affects the progression of kidney disease.

Between January 1, 2014 and June 30, 2020, 51 patients who initiated RRT due to AKI after trauma were enrolled in this study. TBI was identified in 20 patients, and the clinical conditions were not related to TBI in the remaining 31. The study endpoint was set to determine whether the patients of each group needed RRT persistently at discharge and at the time of recent outpatient clinic. Six (30.0%) out of 20 patients with TBI and 2 (6.5%) out of 31 patients without TBI required conventional hemodialysis, as per the most recent data. No significant within-group differences were found in terms of the baseline characteristics and management strategies. In the logistic regression analysis, TBI was independently associated with disease progression to end-stage renal disease. TBI is a risk factor for end-stage renal disease in patients with trauma and stage 3 AKI who initiate RRT.

Abbreviations: AKI = acute kidney injury, APACHE II = Acute Physiologic Assessment and Chronic Health Evaluation II, CKD = chronic kidney disease, ESRD = end-stage renal disease, ISS = injury severity score, KDIGO = Kidney Disease Improving Global Outcomes, RRT = renal replacement therapy, TBI = traumatic brain injury.

Keywords: end-stage renal disease, renal replacement therapy, traumatic brain injury

1. Introduction
Acute kidney injury (AKI) is one of the most common complications seen in critically ill patients. Several studies have reported that the incidence of AKI in patients with trauma varies from 1% to 50%.[1–5] This broad range is probably due to the heterogeneous AKI criteria used, the differences in the trauma severity, and the length of the follow-up period.[6] Patients with trauma are highly exposed to conditions aggravating kidney injury, such as shock, ischemia, reperfusion, nephrotoxic agents, abdominal compartment syndrome, and direct kidney injury. Emergency laparotomy, interventions, or systemic infections throughout resuscitation trigger these initial AKI risk factors, which leads to impaired renal function. [7]

AKI is associated with prolonged intensive care unit stay and a significantly higher risk of mortality, which increases public health expenses.[6] As such, many studies have been conducted on AKI in patients with severe trauma; however, few studies have focused on long-term outcomes, especially, disease progression to end-stage renal disease (ESRD).

Recent studies proposed that the traumatic brain injury (TBI) is associated with impaired renal function.[9] However, this association between TBI and renal disease progression to chronic kidney disease (CKD) or ESRD is not well-known.

In this study, we classified patients with trauma of stage 3 AKI, as per the Kidney Disease Improving Global Outcomes (KDIGO) guidelines, who initiated renal replacement therapy (RRT) into 2 groups depending on the presence of TBI. Comparing the baseline characteristics and management strategies of each groups, we analyzed whether TBI affects the disease progression.

2. Methods
2.1. Ethics
This retrospective observational study was based on data obtained from the registry of a single level 1 trauma center. The study protocol was approved by the Institutional Review Board.
2.2. Study design and population

Between January 1, 2014 and June 30, 2020, 123 patients underwent RRT due to AKI after trauma, which corresponds to stage 3 AKI according to KDIGO guideline (Table 1). To clarify the long-term outcomes of the enrolled patients, we excluded 48 patients who expired following the discontinuation of life-sustaining treatment within 24 hours. We also excluded 18 patients with a history of known CKD, which might influence the outcome as confounding factors. Moreover, 6 patients whose initial diagnosis was not related to trauma were excluded. Finally, 51 patients were enrolled in this study; TBI was identified in 20 patients, and in the remaining 31, the clinical conditions were not related to TBI. Figure 1 shows the study enrollment flow.

2.3. Definitions and study endpoints

RRT includes both continuous RRT and conventional hemodialysis. We administered continuous RRT to all registered patients at the initiation of resuscitative treatment and then converted to hemodialysis after hemodynamic stability was achieved. The primary endpoint of this study was disease progression to ESRD, which was defined as glomerular filtration rate <15 mL/min/1.73 m² or treatment by dialysis for at least 90 days. We examined whether to provide RRT at discharge and at the latest outpatient clinic follow-up point.

2.4. Statistical analyses

The categorical variables were represented as frequencies and percentages, and the continuous variables were reported as medians and ranges. The categorical variables were compared using the chi-squared test or Fisher exact test (when the chi-squared test was not available). The continuous variables were compared using the Student t test or Mann–Whitney test, based on the distribution of the data. Significant variables (P < .25) in the univariate analysis were analyzed by logistic regression for their association with the disease progression. A P-value of <.05 was considered statistically significant. All statistical analyses were performed using SPSS version 21.0 (IBM Corp., Armonk, NY).

3. Results

3.1. Demographic characteristics of the patients

Of the 123 patients, 72 were excluded based on the study criteria, and consequently, 51 were enrolled. The median age was 55 years and 76.5% of the patients were male. The median injury severity score (ISS) was 25 and the median Acute Physiologic Assessment and Chronic Health Evaluation II (APACHE II) score was 26. Of the total study participants, 39.2% had TBI, 33.3% had hypertension, and 7.8% had diabetes. Forty-six patients required emergency surgeries on multiple sites, and 8 out of 51 patients underwent RRT at discharge as the disease progressed. The median number of follow-up was 489 days. The baseline characteristics of the patients are shown in Table 2.

3.2. Comparison of the patients depending on the presence of TBI

We divided the patients into 2 groups according to the presence of TBI, and the groups were compared for their demographic and clinical characteristics (Table 3). There was no significant difference in the baseline characteristics between the 2 groups, including age, gender, and premedica history. There was no significant difference in terms of ISS and APACHE II scores. In addition, we compared the worst values of clinically-related laboratory data from admission to during RRT. The laboratory values reflecting kidney function and the inflammatory response showed no differences. Both groups were administered with vasopressors to a similar extent. The serum lactate level was higher in the TBI group; however, the difference was not significant. Two patients in the no TBI group required RRT and 6
Table 2
General characteristics of the patients.

| Characteristic          | No TBI (n=31) | TBI (n=20) | P-value |
|-------------------------|---------------|------------|---------|
| Age, median (range)     | 55 (18–84)    | 54 (18–77) | .699    |
| Male sex, n (%)         | 24 (77.4%)    | 15 (75%)  | –       |
| ISS, median (range)     | 22 (5–43)     | 29 (4–50)  | .119    |
| APACHE II, median (range)| 27 (5–41) | 26 (4–39)  | .595    |
| HTN, n (%)              | 10 (32.3%)    | 7 (36%)   | .839    |
| DM, n (%)               | 1 (3.2%)      | 3 (15%)   | .287    |
| HL, n (%)               | 1 (3.2%)      | 1 (5%)    | –       |
| CVA, n (%)              | 1 (3.2%)      | 2 (10%)   | .553    |
| CAD, n (%)              | 2 (6.5%)      | 2 (10%)   | .640    |
| Malignancy, n (%)       | 1 (3.2%)      | 2 (10%)   | .553    |
| Vasopressor, n (%)      | 28 (90.3%)    | 18 (90%)  | –       |
| Lactate (mmol/L), median (range) | 4.80 (1.00–14.00) | 6.05 (0.90–15.00) | .429 |
| CRP (mg/L), median (range) | 26.19 (4.37–46.22) | 29.235 (5.19–43.05) | .385 |
| PCT (ng/mL), median (range) | 8.38 (0.33–154.99) | 6 (0.42–403.90) | .805 |
| BUN (mg/dl), median (range) | 85.6 (25.60–183.30) | 83.9 (23.90–159.90) | .938 |
| Cr (mg/dL), median (range) | 5 (1.38–11.75) | 5 (1.9–13.11) | .602 |
| GFR (mL/min/1.73 m²), median (range) | 12 (1.00–57.00) | 14.5 (4.00–53.00) | .595 |
| ICU days, median (range) | 34 (4–131) | 37.5 (3–253) | .582 |
| RRT at discharge, n (%) | 8 (15.7%)     | 15 (75%)  | .287    |

Table 3
Comparison of patient groups according to traumatic brain injury.

| Variables                             | No TBI (n=31) | TBI (n=20) | P-value |
|---------------------------------------|---------------|------------|---------|
| GFR (mL/min/1.73 m²), median (range) | 12 (1.00–57.00) | 14.5 (4.00–53.00) | .595 |
| ICU days, median (range)              | 34 (4–131) | 37.5 (3–253) | .582 |
| RRT at discharge, n (%)               | 8 (15.7%)     | 15 (75%)  | .287    |

4. Discussion

Based on previous studies that investigated the relationship between TBI and renal function, we compared and analyzed the enrolled patients according to whether they had TBI. We found that patients with TBI required persistent RRT at discharge and at the latest outpatient clinic points, which was significantly more than in those without TBI. In this study, 8 patients with trauma required RRT, and the sole risk factor of persistent RRT due to disease progression was TBI. All other variables appeared to have no significant difference among patients with or without TBI. Moreover, the 2 groups showed no difference in the APACHE II and ISS scores, implying that the injuries were of the same magnitude. In order to find the cause of the significant difference in the results, we further investigated the treatment strategies of the patient groups, but none of the variables showed a significant difference, including fluid and nephrotoxic drug usage, which was observed only in a single patient of the persistent RRT group.
Table 4
Logistic regression analysis of risk factors for persistent renal replacement therapy.

| Variables      | Odds ratio | 95% CI      | P-value |
|----------------|------------|-------------|---------|
| Age            | 1.043      | 0.970–1.121 | .253    |
| Male sex       | 1.597      | 1.172–14.793| .680    |
| ISS            | 1.020      | 0.940–1.106 | .634    |
| TBI            | 6.316      | 1.054–37.836| .044    |
| HTN            | 0.749      | 0.066–8.493 | .816    |
| CRP            | 1.092      | 0.976–1.221 | .123    |

CI = confidence interval, CRP = C-reactive protein, HTN = hypertension, ISS = Injury severity score, TBI = traumatic brain injury.

Although the mechanism of AKI in patients with TBI have not been fully elucidated, it can be considered from 2 main perspectives, trauma and brain injury. First, patients with trauma are highly exposed to conditions aggravating kidney injury, such as hypovolemic shock, frequent use of nephrotoxic agents for diagnosis, and direct kidney injury. Routinely administered medications such as NSAIDs also deteriorate kidney function. Second, brain injury leads to excessive secretion of antidiuretic hormone, causing hyponatremia and fluid imbalance. In addition, stimulated sympathetic nervous activity with increased level of plasma catecholamine, results in hypertension with decreased kidney perfusion. Inflammatory cascades after brain injury converged with complement activation and inflammatory cytokine release. These proinflammatory mediators pass the damaged blood brain barrier into systemic circulation, causing organ injury. Civilett et al. carried out an in vitro study with human tubular epithelial cells to clarify the association between severe TBI and acute tubular injury. This study showed that the inflammatory process associated with TBI correlates with renal function. TBI triggers a complex cascade of cellular events, leading to systemic inflammation and damage of kidney and other organs. Civilett et al. also mentioned that this hypothesis might be supported by the increased neutrophil gelatinase-associated lipocalin level, which was significantly elevated, even if biomarkers currently used for the diagnosis of AKI appeared to be within the normal range. Although it cannot be considered statistically meaningful due to the small number of subjects, the correlation between inflammatory markers and kidney disease progression also can be glimpsed in the Table 5. Concerning inflammatory markers, it is difficult to explain the significant difference of CRP level using only the data collected in this study. If additional profound research is conducted on the pathophysiology of TBI, the 2 clinical findings that show significant differences, high degree of inflammation and consequent severely elevated eGFR based on the MDRD study, would be the most conceivable candidates of fundamental risk factors. Further studies from this perspective verify the anticipation.

AKI to CKD transition is mainly caused by maladaptive repair of kidney injury. This process includes many pathophysiological processes, for example, cell death or acute tubular necrosis, renal fibrosis, which are characterized by the accumulation of extra cellular matrix, capillary rarefaction by endothelial to mesenchymal transition, tubular epithelial cell senescence, and consequent inflammatory processes. However, the circumstances under which the disease progresses into ESRD has not been precisely evaluated. Nonetheless, a recent study provided clues to estimate the conditions of disease progression.

Wu et al. performed a retrospective observational analysis of long-term renal outcomes of patients with TBI and found that patients with TBI developed significantly more CKD than those without; however, there was no difference in the progression to ESRD. The study covered nationwide population of patients with TBI regardless of kidney function, whereas we focused on

Table 5
Comparison of patients with traumatic brain injury according to the status of persistent renal replacement therapy.

| Variables       | No RRT (n=14) | RRT (n=6) | P-value |
|-----------------|---------------|-----------|---------|
| Age, median (range) | 53.5 (18–76)  | 64.5 (33–77) | .173    |
| Male sex, n (%)      | 11 (78.6%)    | 4 (66.7%)  | .613    |
| ISS, median (range)  | 29.5 (4–50)   | 19.5 (9–43) | .456    |
| APACHE II, median (range) | 26 (6–15) | 24 (4–29)  | .231    |
| AIS, head, median    | 3.5 (2–6)     | 4 (3–5)    | .391    |
| HTN, n (%)           | 4 (28.6%)     | 3 (50.0%)  | .613    |
| DM, n (%)            | 3 (21.4%)     | 0 (0.0%)   | .521    |
| Hb, n (%)            | 1 (7.1%)      | 0 (0.0%)   | –       |
| CVA, n (%)           | 2 (14.3%)     | 0 (0.0%)   | –       |
| CAD, n (%)           | 2 (14.3%)     | 0 (0.0%)   | –       |
| Malignancy, n (%)    | 0 (0.0%)      | 2 (33.3%)  | .079    |
| Operation, n (%)     | 13 (92.9%)    | 5 (83.3%)  | .521    |
| Vasopressor, n (%)   | 12 (85.7%)    | 6 (100.0%) | –       |
| Lactate (mmol/L), median (range) | 6.45 (0.9–15.0) | 3.80 (2.06–8.20) | .302 |
| CRP (mg/L), median (range) | 27.36 (5.19–39.57) | 35.06 (25.78–43.05) | .013 |
| PCT (ng/mL), median (range) | 6.00 (0.42–55.80) | 7.96 (0.89–403.90) | .888 |
| BUN (mg/dL), median (range) | 66.9 (23.9–159.9) | 109.3 (60.2–154.9) | .248 |
| Cr (mg/dL), median (range) | 3.62 (1.19–8.54) | 6.33 (4.46–13.11) | .058 |
| GFR (mL/min/1.73 m²), median (range) | 17.5 (8–53) | 7.5 (4–29) | .002 |
| ICU days, median (range) | 37.5 (3–253) | 32 (15–69) | .620 |

AS = Abbreviated Injury Scale, APACHE II = Acute Physiologic Assessment and Chronic Health Evaluation II, BUN = blood urea nitrogen, CAD = coronary artery disease, Cr = creatinine, CRP = C-reactive protein, CVA = cerebrovascular accident, DM = diabetes mellitus, GFR = glomerular filtration rate, Hb = hemoglobin, HTN = hypertension, ICU = intensive care unit, ISS = Injury severity score, PCT = procalcitonin, RRT = renal replacement therapy.
patients with stage 3 AKI who initiated RRT at the critical phase of management. The estimated reason for the difference in the result comes from the kidney function of enrolled patients at the starting point of analysis. In future studies, significant conclusions about long-term kidney function might be drawn through the analysis in accordance with the presence or absence of TBI in each AKI stage as per KDIGO guideline. These results would be highly versatile in terms of their clinical implications and may enable to anticipate the graft function of the brain-dead kidney donors.\footnote{15}

A considerable limitation of this study is the heterogeneity in the management; patients with TBI were managed mainly by neurosurgeons and those without TBI were managed by general surgeons. Therefore, consistent treatments were not applied to the study patients. In addition, this study was a retrospective analysis conducted using registry data from a single trauma center and consisted of a relatively small number of patients in each group. Thus, selection and information biases might have affected the results. Moreover, the diagnosis of AKI and initiation of RRT were based on patients’ clinical status judged by diverse physicians. It was also a limitation of this study that long-term follow-up of the patients was not performed.

5. Conclusion

TBI is a risk factor for ESRD in patients with trauma who develop stage 3 AKI, as per the KDIGO guideline. TBI patients might benefit by prudent monitoring of kidney function and early detection of disease. Through early initiation of multidisciplinary management, especially with nephrology, it is possible to reduce the possibility of disease progression by restricting clinical conditions that can cause nephrotoxicity while maintaining volume status.

Author contributions

Conceptualization: Kyunghak Choi, Kyu-Hyouck Kyoung, Jihoon T Kim.

Data curation: Min Soo Kim, Min Ae Keum, Seongho Choi, Sungjeep Kim.

Formal analysis: Kyunghak Choi.

Methodology: Kyu-Hyouck Kyoung.

Project administration: Minsu Noh.

References

[1] Shashaty MGS, Meyer NJ, Localio AR, et al. African American race, obesity, and blood product transfusion are risk factors for acute kidney injury in critically ill trauma patients. J Crit Care 2012;27:496–504.

[2] Elterman J, Zonies D, Stewart I, Fang R, Schreiber M. Rhabdomyolysis and acute kidney injury in the injured war fighter. J Trauma Acute Care Surg 2015;79(Suppl 2):S171–4.

[3] Podoll AS, Koazar R, Holcomb JB, Finkel KW. Incidence and outcome of early acute kidney injury in critically-ill trauma patients. PLoS One 2013;8:e77376.

[4] Eriksson M, Brattström O, Mårtensson J, Larsson E, Oldner A. Acute kidney injury following severe trauma: risk factors and long-term outcome. J Trauma Acute Care Surg 2015;79:407–12.

[5] Skinner DL, Hardcastle TC, Rodseth RN, Muckart DJ. The incidence and outcomes of acute kidney injury amongst patients admitted to a level I trauma unit. Injury 2014;45:259–64.

[6] Harrois A, Libert N, Duranteau J. Acute kidney injury in trauma patients. Curr Opin Crit Care 2017;23:447–56.

[7] Harrois A, Soyer B, Gauss T, et al. Prevalence and risk factors for acute kidney injury among trauma patients: a multicenter cohort study. Crit Care 2018;22:344.

[8] Haines RW, Fowler AJ, Kirwan CJ, Prowle JR. The incidence and associations of acute kidney injury in trauma patients admitted to critical care: a systematic review and meta-analysis. J Trauma Acute Care Surg 2019;86:141–7.

[9] Moore EM, Bellomo R, Nichol A, Harley N, Macisac C, Cooper DJ. The incidence of acute kidney injury in patients with traumatic brain injury. Ren Fail 2010;32:1060–5.

[10] Wu CL, Kor CT, Chiu PF, et al. Long-term renal outcomes in patients with traumatic brain injury: a nationwide population-based cohort study. PLoS One 2017;12:e0171999.

[11] Baker SP, O’Neill B, Haddon W Jr, Long WB. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma 1974;14:187–96.

[12] Ghirnikar RS, Lee YL, Eng LF. Inflammation in traumatic brain injury: role of cytokines and chemokines. NeuroRx 1998;23:329–40.

[13] Civilett F, Assenzio B, Mazzeo AT, et al. Acute tubular injury is associated with severe traumatic brain injury: in vitro study on human tubular epithelial cells. Sci Rep 2019;9:6090.

[14] Kurzhagen JT, Dellepiane S, Cantaluppi V, Rabh H. AKI: an increasingly recognized risk factor for CKD development and progression. J Nephrol 2020;33:1171–87.

[15] Nongnuch A, Panorchan K, Davenport A. Brain-kidney crosstalk. Crit Care 2014;18:225.